Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ERN1 | O75460 | 11/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15766289 | 0.86 | ERN1 (0.47) | CYP3A4MAPK1ERN1ALDH1A1MEN1 | |
| SCHEMBL27759119 | 0.84 | ALDH1A1 (0.52) | CYP3A4MAPK1ERN1ALDH1A1MEN1 | |
| SCHEMBL1413983 | 0.82 | CYP3A4 (0.52) | CYP3A4MAPK1ERN1ALDH1A1MEN1 | |
| SCHEMBL30498483 | 0.82 | ALDH1A1 (0.44) | CYP3A4MAPK1ERN1ALDH1A1MEN1 | |
| SCHEMBL189622 | 0.80 | ALDH1A1 (0.59) | CYP3A4MAPK1ERN1ALDH1A1MEN1 | |
| SCHEMBL5647051 | 0.78 | ALDH1A1 (0.41) | CYP3A4MAPK1ERN1ALDH1A1MEN1 | |
| SCHEMBL21884804 | 0.78 | ERN1 (0.44) | CYP3A4MAPK1ERN1ALDH1A1MEN1 | |
| SCHEMBL275539 | 0.78 | ALDH1A1 (0.41) | CYP3A4MAPK1ERN1ALDH1A1MEN1 | |
| SCHEMBL1359286 | 0.78 | ERN1 (0.44) | CYP3A4MAPK1ERN1ALDH1A1MEN1 | |
| SCHEMBL26093783 | 0.78 | ERN1 (0.44) | CYP3A4MAPK1ERN1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371434-B2 | MLL1 inhibitors and anti-cancer agents | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) | 2025-07-29 | — | — | US | disclosed |
| CN-114929705-B | MLL1 inhibitors and anticancer agents | 诺华公司 | 2024-09-13 | — | — | CN | disclosed |
| EP-4013754-B1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2024-07-24 | — | — | EP | disclosed |
| US-20230121768-A1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) | 2023-04-20 | — | — | US | disclosed |
| CN-109890797-B | Substituted carbon nucleoside derivatives useful as anticancer agents | 辉瑞公司 | 2023-02-28 | — | — | CN | disclosed |
| CN-114929705-A | MLL1 inhibitor and anticancer agent | 诺华公司 | 2022-08-19 | — | — | CN | disclosed |
| EP-4013754-A1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | Novartis AG (CH) | 2022-06-22 | — | — | EP | disclosed |
| WO-2021239077-A1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2021-12-02 | — | — | WO | disclosed |
| WO-2021239077-A1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2021-12-02 | — | — | WO | disclosed |
| EP-3464249-B1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2021-08-11 | — | — | EP | disclosed |
| WO-2002085459-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-31 | — | — | WO | disclosed |
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2002-08-01 | — | — | US | disclosed |
| US-20020010206-A1 | Substituted benzopyran analogs for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2002-01-24 | — | — | US | disclosed |
| EP-1123285-A1 | SUBSTITUTED BENZOPYRAN ANALOGS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 2001-08-16 | — | — | EP | disclosed |
| US-6271253-B1 | CYCLOOXYGENASE INHIBITORS | G.D. SEARLE & CO. | 2001-08-07 | — | — | US | disclosed |
| US-6077850-A | USEFUL FOR TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS, SUCH AS INFLAMMATION AND INFLAMMATION-RELATED DISORDERS | G.D. SEARLE & CO. (US) | 2000-06-20 | — | — | US | disclosed |
| WO-2000023433-A1 | SUBSTITUTED BENZOPYRAN ANALOGS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 2000-04-27 | — | — | WO | disclosed |
| US-6034256-A | CYCLOOXYGEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-03-07 | — | — | US | disclosed |
| EP-0977748-A1 | SUBSTITUTED BENZOPYRAN DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 2000-02-09 | — | — | EP | disclosed |
| WO-1998047890-A1 | SUBSTITUTED BENZOPYRAN DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371434-B2 | MLL1 inhibitors and anti-cancer agents | MLLT1, BMI1, DOT1L | CYP3A4 4293/4885MAPK1 190/4885ERN1 1060/4885 |
| US-20020010206-A1 | Substituted benzopyran analogs for the treatment of inflammation | PTGS1, IL1R1, PTGES2 | CYP3A4 379/4885MAPK1 1185/4885ERN1 2255/4885 |
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | TOP2A, TOP2B, TOP1 | CYP3A4 2709/4885MAPK1 3605/4885ERN1 4491/4885 |
| US-20230121768-A1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | MLLT1, BMI1, DOT1L | CYP3A4 4293/4885MAPK1 190/4885ERN1 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.